Surprises and omissions in toxicology

Area of Science:

• Pharmacology
• Toxicology
• Immunology

Background:

• Explores historical, often overlooked, research findings on drug interactions with bacterial toxins.
• Investigates the pharmacokinetic and pharmacodynamic effects of bacterial toxins on drug efficacy.
• Highlights the unique therapeutic potential of adenosine triphosphate (ATP) as an antagonist to bacterial toxins, even when administered post-exposure.

Discussion:

• Compares the clinical efficacy of different forms of cycloserine, emphasizing the importance of stereoisomer specificity.
• Evaluates the antitumor properties of 6-azauracil riboside and its derivatives, noting a lack of efficacy but excellent tolerance.
• Discusses the repurposing of 6-azauracil derivatives for autoimmune diseases like psoriasis and rheumatoid arthritis, citing mixed results due to toxicity.

Key Insights:

• Bacterial toxins can significantly alter drug pharmacokinetics and pharmacodynamics, a factor often overlooked in clinical trial designs focused solely on healthy volunteers.
• Adenosine triphosphate (ATP) demonstrates a unique therapeutic window as an antagonist to bacterial toxins, effective even after toxin administration.
• While 6-azauracil derivatives showed no antitumor activity, their excellent tolerance profile prompted investigations into autoimmune conditions, though high toxicity limited rheumatoid arthritis trials.

Outlook:

• Re-evaluation of historical data can uncover novel therapeutic strategies and drug interactions.
• Further research into adenosine triphosphate (ATP) mechanisms may yield new treatments for toxin-induced conditions.
• Careful dose-ranging and toxicity studies are crucial for repurposing drugs, especially in autoimmune diseases.